VolitionRX Ltd VNRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
-
VolitionRx Participates in Launch of DETECSEPS Program in France
-
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
-
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
-
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
-
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
-
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
-
Volition Advances Nu.Q® NETs Platform Towards Commercialization
Trading Information
- Previous Close Price
- $0.24
- Day Range
- $0.23–0.24
- 52-Week Range
- $0.23–13.20
- Bid/Ask
- $0.24 / $0.24
- Shares Outstanding
- 30.06M
- Market Cap
- $7.19M
- Volume/Avg
- 450,196 / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 75
- Website
- https://www.volition.com
Valuation
|
Metric
|
VNRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.66 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VNRX
|
|---|---|
Quick Ratio | 0.23 |
Current Ratio | 0.30 |
Interest Coverage | −6.02 |
Quick Ratio
VNRX
Profitability
|
Metric
|
VNRX
|
|---|---|
Return on Assets (Normalized) | −276.43% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
VNRX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|Zl!@?Hn | LOCK|BpZT | $169B | |||
| Medtronic PLC
MDT
| LOCK|YZLDt$d | LOCK|LT&y | $110B | |||
| Stryker Corp
SYK
| LOCK|nN$f?s>P | LOCK|Jc | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|BzXQdjP | LOCK|F$bH | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|wg>#h$K< | LOCK|<x#? | $49B | |||
| DexCom Inc
DXCM
| LOCK|sD^spgR | LOCK|!vmV | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|>&>!%>? | LOCK|wlh | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|<!c | LOCK|CK | $23B | |||
| Steris PLC
STE
| LOCK|&<><b$t | LOCK|%<&v | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|yHvN$!v | LOCK|<^ | $17B |
United States